Clinical Trial: SOX as Salvage Treatment in Nasopharyngeal Carcinoma
Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional
Official Title: Phase II Study of SOX in Patients With Platinum-resistant Nasopharyngeal Carcinoma
Brief Summary: The aim of the study is to evaluate the efficacy and safety of SOX regimen (S-1 plus oxaliplatin) as salvage treatment in patients with relapsed or metastatic nasopharyngeal carcinoma.
Detailed Summary: The treatment option in patients with platinum-resistant relapsed or metastatic nasopharyngeal carcinoma is limited. Previous studies showed that both S-1 and oxaliplatin were effective in head and neck cancer. Moreover, SOX (S-1 plus oxaliplatin) was proved to be tolerable in advanced stage gastric cancer. Therefore, we aim to evaluate this regimen in salvage setting of nasopharyngeal carcinoma.
Sponsor: Fudan University
Current Primary Outcome: Median progression-free survival [ Time Frame: 1 year ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Overall response rate [ Time Frame: 6 weeks ]
- Median overall survival [ Time Frame: 1.5 year ]
Original Secondary Outcome: Same as current
Information By: Fudan University
Dates:
Date Received: July 26, 2011
Date Started: July 2011
Date Completion: December 2015
Last Updated: August 19, 2014
Last Verified: August 2014
